MannKind (NASDAQ:MNKD) and Vitro Diagnostics (OTCMKTS:VODG) Critical Contrast

MannKind (NASDAQ:MNKD) and Vitro Diagnostics (OTCMKTS:VODG) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Institutional & Insider Ownership

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by insiders. Comparatively, 27.7% of Vitro Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MannKind and Vitro Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MannKind	-6.63%	-11.21%	-3.92%
Vitro Diagnostics	-427.15%	N/A	-191.89%

Earnings and Valuation

This table compares MannKind and Vitro Diagnostics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97 million	2.93	$5.86 million	($0.07)	-47.29
Vitro Diagnostics	$2.06 million	N/A	-$10.85 million	($2.21)	-0.18

MannKind has higher revenue and earnings than Vitro Diagnostics. MannKind is trading at a lower price-to-earnings ratio than Vitro Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for MannKind and Vitro Diagnostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	1	2	7	0	2.60
Vitro Diagnostics	0	0	0	0	0.00

MannKind currently has a consensus price target of $8.84, suggesting a potential upside of 167.18%. Given MannKind’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MannKind is more favorable than Vitro Diagnostics.

Summary

MannKind beats Vitro Diagnostics on 9 of the 11 factors compared between the two stocks.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

About Vitro Diagnostics

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.